Literature DB >> 21532547

Reflections on the Innovative Medicines Initiative.

Michel Goldman1.   

Abstract

The pharmaceutical industry is developing new collaborative models for drug development. This article discusses the experience so far of the Innovative Medicines Initiative, which is currently the largest public-private partnership that is dedicated to pharmaceutical innovation, highlighting lessons learned for the success of precompetitive consortia.

Mesh：

Year:  2011        PMID： 21532547     DOI： 10.1038/nrd3434

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  2 in total

1.  Schizophrenia: The drug deadlock.

Authors:  Alison Abbott
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

Review 2.  Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).

Authors:  Elisabeth H Bel; Ana Sousa; Louise Fleming; Andrew Bush; K Fan Chung; Jennifer Versnel; Ariane H Wagener; Scott S Wagers; Peter J Sterk; Chris H Compton
Journal:  Thorax       Date:  2010-11-23       Impact factor: 9.139
  2 in total
  9 in total

1.  Expanding precompetitive space.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2011-12       Impact factor: 84.694

2.  Integrating pharmacology and clinical pharmacology in pharmaceutical companies.

Authors:  Jackie A Hunter
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

3.  Metrics survey of industry-sponsored clinical trials in Canada and comparator jurisdictions between 2005 and 2010.

Authors:  Jean-Marie Leclerc; Normand Laberge; Jean Marion
Journal:  Healthc Policy       Date:  2012-11

4.  Inhibition of the dapE-Encoded N-Succinyl-L,L-diaminopimelic Acid Desuccinylase from Neisseria meningitidis by L-Captopril.

Authors:  Anna Starus; Boguslaw Nocek; Brian Bennett; James A Larrabee; Daniel L Shaw; Wisath Sae-Lee; Marie T Russo; Danuta M Gillner; Magdalena Makowska-Grzyska; Andrzej Joachimiak; Richard C Holz
Journal:  Biochemistry       Date:  2015-08-03       Impact factor: 3.162

5.  Unraveling the autoimmune translational research process layer by layer.

Authors:  Richard S Blumberg; Bonnie Dittel; David Hafler; Matthias von Herrath; Frank O Nestle
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

Review 6.  StemBANCC: Governing Access to Material and Data in a Large Stem Cell Research Consortium.

Authors:  Michael Morrison; Christine Klein; Nicole Clemann; David A Collier; John Hardy; Barbara Heisserer; M Zameel Cader; Martin Graf; Jane Kaye
Journal:  Stem Cell Rev Rep       Date:  2015-10       Impact factor: 5.739

7.  "A good collaboration is based on unique contributions from each side": assessing the dynamics of collaboration in stem cell science.

Authors:  Michael Morrison
Journal:  Life Sci Soc Policy       Date:  2017-05-04

8.  New Insights in Computational Methods for Pharmacovigilance: E-Synthesis, a Bayesian Framework for Causal Assessment.

Authors:  Francesco De Pretis; Barbara Osimani
Journal:  Int J Environ Res Public Health       Date:  2019-06-24       Impact factor: 3.390

Review 9.  The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.

Authors:  Hugh Laverty; Pierre Meulien
Journal:  Front Med (Lausanne)       Date:  2019-12-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.